Zacks Research Forecasts Weaker Earnings for Haemonetics

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for shares of Haemonetics in a report released on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $1.19 per share for the quarter, down from their previous estimate of $1.22. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.59 EPS, Q1 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.32 EPS, FY2026 earnings at $5.17 EPS and Q1 2027 earnings at $1.48 EPS.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.99 EPS.

Several other brokerages also recently commented on HAE. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Friday, November 8th. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. CL King assumed coverage on Haemonetics in a research report on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a research report on Friday, November 15th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $107.88.

Haemonetics Stock Performance

NYSE HAE opened at $87.48 on Monday. The business’s 50 day moving average price is $80.21 and its 200-day moving average price is $82.00. The company has a market cap of $4.39 billion, a P/E ratio of 36.30, a P/E/G ratio of 1.36 and a beta of 0.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a fifty-two week low of $70.25 and a fifty-two week high of $97.97.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in Haemonetics by 26.8% during the first quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock worth $2,536,000 after buying an additional 6,287 shares in the last quarter. First Hawaiian Bank boosted its holdings in shares of Haemonetics by 55.2% during the second quarter. First Hawaiian Bank now owns 6,165 shares of the medical instruments supplier’s stock worth $510,000 after purchasing an additional 2,192 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Haemonetics by 311.4% during the second quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock worth $2,132,000 after purchasing an additional 19,510 shares during the last quarter. CWM LLC boosted its holdings in shares of Haemonetics by 40.5% during the second quarter. CWM LLC now owns 36,526 shares of the medical instruments supplier’s stock worth $3,022,000 after purchasing an additional 10,537 shares during the last quarter. Finally, Cardinal Capital Management boosted its holdings in shares of Haemonetics by 3.8% during the second quarter. Cardinal Capital Management now owns 14,832 shares of the medical instruments supplier’s stock worth $1,227,000 after purchasing an additional 549 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.